Laser treatment for genitourinary syndrome of menopause: Scientific Impact Paper No. 72 (July 2022): Scientific Impact Paper No. 72 (July 2022).
Journal
BJOG : an international journal of obstetrics and gynaecology
ISSN: 1471-0528
Titre abrégé: BJOG
Pays: England
ID NLM: 100935741
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
pubmed:
28
7
2022
medline:
19
10
2022
entrez:
27
7
2022
Statut:
ppublish
Résumé
Genitourinary syndrome of menopause (GSM) is the term used to describe the group of symptoms including vaginal pain, vaginal dryness, itching, pain during sexual intercourse and fragile vaginal tissues as well as urinary symptoms including urinary frequency, urgency, incontinence, blood in the urine (haematuria) and recurrent urinary tract infections that occur due to a lack of the hormone estrogen. These symptoms can have a significant negative impact on psychosexual issues, sexual function and quality of life in postmenopausal women. Traditionally women have been treated with vaginal lubricants, vaginal moisturisers or low-dose vaginal estrogens. Lasers have been used in the cosmetic industry for collagen remodelling and repair of the skin. Therefore, it has been suggested that laser therapy may be used on the vagina as an alternative treatment for GSM. A review of all the published studies assessing the safety and efficacy of laser therapy for GSM have shown promising beneficial results. The majority of studies to date have been small, short-term, observational studies. However, there are randomised controlled trials underway. Laser treatment may be beneficial for the symptoms of GSM but until more robust evidence is available it should not be adopted into widespread practice, and should be used as part of a research study only.
Identifiants
pubmed: 35892242
doi: 10.1111/1471-0528.17195
doi:
Substances chimiques
Estrogens
0
Lubricants
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e89-e94Informations de copyright
© 2022 Royal College of Obstetricians and Gynaecologists.
Références
US Food and Drug Administration [cited 22 Apr 2021]. Available from: https://www.fda.gov/medical-devices/safety-communications/fda-warns-against-use-energy-based-devices-perform-vaginal-rejuvenation-or-vaginal-cosmetic
Hillard TC, Nappi RE. The heat is on. Climacteric. 2020;23:S1-2.
Preti M, Vieira-Baptista P, Digesu GA, Bretschneider CE, Damaser M, Demirkesen O, et al. The clinical role of LASER for vulvar and vaginal treatments in gynecology and female urology: an ICS/ISSVD best practice consensus document. NeurourolUrodyn. 2019;38:1009-23.
Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016;215:704-11.
Hutchinson-Colas J, Segal S. Genitourinary syndrome of menopause and the use of laser therapy. Maturitas. 2015;82:342-5.
Zerbinati N, Serati M, Origoni M, Candiani M, Iannitti T, Salvatore S, et al. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci. 2015;30:429-36.
Pitsouni E, Grigoriadis T, Douskos A, Kyriakidou M, Falagas ME, Athanasiou S. Efficacy of vaginal therapies alternative to vaginal estrogens on sexual function and orgasm of menopausal women: a systematic review and meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 2018;229:45-56.
Jha S, Wyld L, Krishnaswamy PH. The impact of vaginal laser treatment for genitourinary syndrome of menopause in breast cancer survivors: a systematic review and meta-analysis. Clin Breast Cancer. 2019;19:e556-62.
Jha S, Hillard T. Energy devices in vaginal therapy. TOG. 2019;21:233-6.
Bhide AA, Khullar V, Swift S, Digesu GA. The use of laser in urogynaecology. Int Urogynecol J. 2019;30(5):683-92.
Phillips C, Hillard T, Salvatore S, Toozs-Hobson CL. Lasers in gynaecology. Eur J Obstet Gynecol Reprod Biol. 2020;251:146-55.
Tadir Y, Gaspar A, Lev-Sagie A, Alexiades M, Alinsod R, Bader A, et al. Light and energy based therapeutics for genitourinary syndrome of menopause: consensus and controversies. Lasers Surg Med. 2017;49:137-59.
Arunkalaivanan A, Kaur H, Onuma O. Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence. Int Urogynecol J. 2017;28:681-5.
Salvatore S, Maggiore ULR, Athanasiou S, Origoni M, Candiani M, Calligaro A, et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. Menopause. 2015;22:845-9.
Lapii GA, Yakovleva AY, Neimark AI. Structural reorganization of the vaginal mucosa in stress urinary incontinence under conditions of Er:YAG laser treatment. Bull Exp Biol Med. 2017;162:510-4.
Gaspar A, Addamo G, Brandi H. Vaginal fractional CO2 laser: a minimally invasive option for vaginal rejuvenation. Am J Cosmetic Surg. 2011;28:156-62.
Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Origoni M, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric. 2014;17:363-9.
Salvatore S, Nappi RE, Parma M, Chionna R, Lagona F, Zerbinati N, et al. Sexual function after fractional microablative CO2 laser in women with vulvovaginal atrophy. Climacteric. 2015;18(2):219-25.
Perino A, Calligaro A, Forlani F, Tiberio C, Cucinella G, Svelato A, et al. Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser. Maturitas. 2015;80:296-301.
Sokol ER, Karram MM. Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes. Menopause. 2017;24:810-4.
Behnia-Willison F, Sarraf S, Miller J, Mohamadi B, Care AS, Lam A, et al. Safety and long-term efficacy of fractional CO2 laser treatment in women suffering from genitourinary syndrome of menopause. Eur J Obstet Gynecol Reprod Biol. 2017;213:39-44.
Cruz VL, Steiner ML, Pompei LM, Strufaldi R, Fonseca FL, Santiago LH, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause. 2018;25:21-8.
Gambacciani M, Levancini M. Short-term effect of vaginal erbium laser on the genitourinary syndrome of menopause. Minerva Ginecol. 2015;67:97-102.
Gambacciani M, Levancini M, Russo E, Vacca L, Simoncini T, Cervigni M. Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause. Climacteric. 2018;21:148-52.
Gambacciani M, Levancini MB, Cervigni M. Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause. Climacteric. 2015;18:757-63.
Gambacciani M, Levancini M. Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors. Menopause. 2017;24:316-9.
Gaspar A, Brandi H, Gomez V, Luque D. Efficacy of erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. Lasers Surg Med. 2017;49:160-8.
Gaspar A, Maestri S, Silva J, Brandi H, Luque D, Koron N, et al. Intraurethral erbium: YAG laser for the management of urinary symptoms of genitourinary syndrome of menopause: a pilot study. Lasers Surg Med. 2018;50:802-7.
Eder SE. Long-term safety and efficacy of fractional CO2 laser treatment in post-menopausal women with vaginal atrophy. Laser Ther. 2019;28:103-9.
Athanasiou S, Pitsouni E, Grigoriadis T, Zacharakis D, Falagas ME, Salvatore S, et al. Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results. Menopause. 2019;26:248-55.
Politano CA, Costa-Paiva L, Aguiar LB, Machado HC, Baccaro LF. Fractional CO2 laser versus promestriene and lubricant in genitourinary syndrome of menopause: a randomized clinical trial. Menopause. 2019;26:833-40.
Filippini M, Luvero D, Salvatore S, Pieralli A, Montera R, Plotti F, et al. Efficacy of fractional CO2 laser treatment in postmenopausal women with genitourinary syndrome: a multicenter study. Menopause. 2020;27:43-9.
Paraiso MF, Ferrando CA, Sokol ER, Rardin CR, Matthews CA, Karram MM, et al. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: the VeLVET trial. Menopause. 2020;27:50-6.
Arêas F, Valadares AL, Conde DM, Costa-Paiva L. The effect of vaginal erbium laser treatment on sexual function and vaginal health in women with a history of breast cancer and symptoms of the genitourinary syndrome of menopause: a prospective study. Menopause. 2019;26:1052-8.
Weber MA, Limpens J, Roovers JP. Assessment of vaginal atrophy: a review. Int Urogynecol J. 2015;261:15-28.
Huang AJ, Gregorich SE, Kuppermann M, Nakagawa S, Van Den Eeden SK, Brown JS, et al. The day-to-day impact of vaginal aging questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women. Menopause. 2015;22:144-54.
Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cut off scores. J Sex Marital Ther. 2005;31:1-20.
Cruff J, Khandwala S. A double-blind randomized Sham-controlled trial to evaluate the efficacy of fractional carbon dioxide laser therapy on genitourinary syndrome of menopause. J Sex Med. 2021;18(4):761-9.
Salvatore S, Pitsouni E, Grigoriadis T, Zacharakis D, Pantaleo G, Candiani M, et al. CO2 laser and the genitourinary syndrome of menopause: a randomized sham-controlled trial. Climacteric. 2021;24(2):187-93.
Li FG, Maheux-Lacroix S, Deans R, Nesbitt-Hawes E, Budden A, Nguyen K, et al. Effect of fractional carbon dioxide laser vs sham treatment on symptom severity in women with postmenopausal vaginal symptoms: a randomized clinical trial. JAMA. 2021;326(14):1381-9.
Laser vs hyaluronic acid for GSM in breast cancer (ClinicalTrials.gov Identifier: NCT03816735) [cited 18 Nov 2021]. Available from: https://clinicaltrials.gov/ct2/show/NCT03816735?term=laser&cond=GSM&draw=2&rank=2
Laser vaginal treatment for GSM (ClinicalTrials.gov Identifier: NCT04042766) [cited 18 Nov 2021]. Available from: https://clinicaltrials.gov/ct2/show/NCT04042766?term=laser&cond=GSM&draw=2&rank=1
Effect of hybrid laser 10600+1540 nm on GSM (ClinicalTrials.gov Identifier: NCT03956563) [cited 18 Nov 2021]. Available from: https://clinicaltrials.gov/ct2/show/NCT03956563?term=laser&cond=GSM&draw=2&rank=5
Flint R, Cardozo L, Grigoriadis T, Rantell A, Pitsouni E, Athanasiou S. Rationale and design for fractional microablative CO2 laser versus photothermal non-ablative erbium: YAG laser for the management of genitourinary syndrome of menopause: a non-inferiority, single-blind randomized controlled trial. Climacteric. 2019;22:307-11.
Gambacciani M, Cervigni M, Gaspar A, Novakov Mikić A, Gaviria J, Koron N, et al. Safety of vaginal erbium laser: a review of 113,000 patients treated in the past 8 years. Climacteric. 2020;23:S28-32.
Ahluwalia J, Avram MM, Ortiz AE. Lasers and energy-based devices marketed for vaginal rejuvenation: a cross-sectional analysis of the MAUDE database. Lasers Surg Med. 2019;51:671-7.
Gordon C, Gonzales S, Krychman ML. Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy. Menopause. 2019;26:423-7.
National Institute for Health and Care Excellence. Transvaginal laser therapy for stress urinary incontinence. NICE Interventional procedures guidance [IPG696]. London: NICE; 2021.
National Institute for Health and Care Excellence. Transvaginal laser therapy for urogenital atrophy. NICE Interventional procedures guidance [IPG697]. London:NICE; 2021.
NHS Health Education England. Developing people for health and healthcare. Part One: Qualification requirements for delivery of cosmetic procedures: non-surgical cosmetic interventions and hair restoration surgery. 2015 [cited 18 Nov 2021]. Available from: https://www.hee.nhs.uk/sites/default/files/documents/HEE%20Cosmetic%20publication%20part%20one.pdf
The Independent Medicines & Medical Devices Safety Review. First do no harm. The report of the Independent Medicines and Medical Devices Safety Review. 2020 [cited 18 Nov 2021]. Available from: https://www.immdsreview.org.uk/Report.html